Vaccine producer and pharmaceutical giant Moderna announced today that they would be partnering with Sanofi to manufacture 200 million doses of the COVID-19 vaccine.
The deal provides that Sanofi will “fill” the vaccine doses at its facility in Ridgefield, New Jersey starting in September 2021. Moderna said they “welcomed the opportunity” to work with Sanofi in a statement made earlier this morning.
Moderna also thanked the Biden Administration and the U.S. Department of Health and Human Services for their support in making the deal possible.
The Moderna vaccine is one of two primary vaccine options for American citizens within the continental U.S., the second being Pfizer. Moderna’s vaccine is mRNA based and is delivered in two doses, like the Pfizer vaccine. Both vaccines require refrigerated storage.
The Johnson & Johnson vaccine was just approved for use again in the U.S. following an Food and Drug Administration review of a rare blood disorder developed by vaccine recipients. It is the third vaccine available for use in the U.S. and, unlike Moderna and Pfizer, does not require refrigerated storage.
The U.S. has seen a steady increase of COVID-19 infection rates, though new case averages are down according to data provided by the New York Times. Infection rates and the 7-day running average are roughly at the same levels they were this time in 2020.
© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.